Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > National Cancer Institute (NCI) Contracts with Aphios to Develop Nannotech Combination Therapy for Certain Cancers

Abstract:
Aphios Corporation today announced that it has entered into a contract with the National Cancer Institute (NCI) to develop Tdp-1 inhibitors either as a primary therapy or in combination with camptothecins for colon, breast, ovarian, leukemia and other cancers. The contract was made through the Small Business Innovative Research (SBIR) Phase I program.

National Cancer Institute (NCI) Contracts with Aphios to Develop Nannotech Combination Therapy for Certain Cancers

Woburn, Massachusetts | Posted on April 8th, 2009

The contract is to develop a combination therapeutic based on research conducted by scientists at the National Cancer Institute who have discovered that the enzyme Tyrosyl-DNA phosphodiesterase (Tdp1) can repair topoisomerase I (Top1)-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond [US Patent Pending]. Inhibiting Tdp1 has the potential to enhance the anticancer activity of topoisomerase I inhibitors such as camptothecins and to act as anti-proliferative agents.

Dr. Yves Pommier, lead scientist of this invention at the NCI states that "The development of Tdp1 inhibitors as anticancer agents can be envisioned as combinations of Tdp1 and Top1 inhibitors. Moreover, Tdp1 inhibitors might also be effective by themselves as anticancer agents."

Scientists at Aphios are developing a co-encapsulation formulation of the selected camptothecin and Tdp1 inhibitor in phospholipid nanosomes (small, uniform liposomes). Camptothecins are quite hydrophobic and will be packaged in the lipid bilayer. Tdp1 inhibitors such as tetracycline and neomycin are quite water-soluble and will be packaged in the aqueous core of phospholipid nanosomes [US Patents and US Patent Pending].
We anticipate that this nanosomal formulation will result in reduced systemic toxicity, due to the masking of the cytotoxic effects of camptothecins and Tdp1 inhibitors. Additionally, the stability of the lactone ring in the nanosomes will be improved as a result of protection from the neutral pH of the blood stream. By increasing residence time in the circulatory system, the nanosomes increase therapeutic efficacy of the combination drugs. Optionally, pegylated phospholipids will be utilized to provide steric hindrance that will further increase residence time and therapeutic efficacy as is done with Doxil®, liposome encapsulated doxorubicin. Furthermore, phospholipids linked with specific antibodies or ligands will be utilized to target the co-encapsulated camptothecin and Tdp1 inhibitor to specific cancers in the colon, lung or ovary. Such smart targeting will further reduce toxicities associated with both Top1 and Tdp1 inhibitors while increasing efficacy and therapeutic index.

The project described herein is supported by NCI Contract No. HHSN-261200800026C (NCI Control No. N43CM-2008-00026). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI and the National Institutes of Health.

####

About Aphios Corporation
Aphios Corporation is a biotechnology company that is developing enabling technology platforms including nanotechnology drug delivery platforms such as phospholipid nanosomes, biodegradable polymer nanospheres, and protein and crystal nanoparticles for the improved delivery of poorly water-soluble anticancer drugs, therapeutic proteins and siRNA molecules, as well as enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and CNS disorders.

For more information, please click here

Contacts:
Dr. Trevor P. Castor
President and CEO
Aphios Corporation
3-E Gill Street, New Boston Park
Woburn, Massachusetts 01801 USA
Tel: (001) (781) 932-6933
Fax: (001) (781) 932-6865

Copyright © Aphios Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Govt.-Legislation/Regulation/Funding/Policy

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

New imaging agent provides better picture of the gut July 25th, 2014

Hysitron is Awarded TWO R&D 100 Awards for Highly Innovative Technology Developments in the Areas of Extreme Environments and Biological Mechanical Property Testing July 23rd, 2014

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

Nanobiotechnology

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Harris & Harris Group Invests in Unique NYC Biotech Accelerator July 29th, 2014

Seeing is bead-lieving: Rice University scientists create model 'bead-spring' chains with tunable properties July 28th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE